SEC Form D private-offering filing

Phio Pharmaceuticals Corp.

Name: Phio Pharmaceuticals Corp. - new SEC Form D private-offering filing, King Of Prussia, PA
Published: 2025-11-12

A new SEC Form D private-offering notice from King Of Prussia, PA, a $25,931,342 filer-stated offering target in Biotech. The source filing is one click away.

Phio Pharmaceuticals Corp. site↗ Verified via SEC Form D

Clinical-stage biopharmaceutical company developing INTASYL siRNA gene silencing therapeutics to enhance immune cells against cancer, including a PD-1 silencing candidate for skin cancers.

Filed 2025-11-12Filed to raise $25,931,342First money in 2025-11-04Raised so far $1,415,796HQ (as filed) King Of Prussia, PASector Biotech ✓Stage (inferred) GrowthCall status Needs classification

Source linked the Form D on EDGAR↗Website verified phiopharma.com↗Named in the filing 6 executives & directors

Open this row on the live feed →More new filings in Pennsylvania →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.